Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.
Carteolol is a relatively potent nonselective beta-adrenoceptor antagonist with partial agonist activity. It is used topically to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Twice-daily ocular administration of carteolol 1 or 2% lowers IOP by approximately 32% on average in patients with these conditions, an efficacy equivalent to that of timolol 0.25 or 0.5%. Carteolol eyedrops lack local anaesthetic activity, appear to cause less local irritation than timolol, and produce less pronounced decreases in heart rate or dyspnoea, possibly due to partial agonist activity. The latter activity may also improve retinal perfusion. Thus, although additional comparative trials are needed to accurately assess the precise place of carteolol in therapy, this drug offers a useful alternative to timolol in the management of conditions associated with a raised IOP, and may have advantages in older patients with regard to its tolerability profile, although careful monitoring is still wise.
Chrisp
P
P
Adis International Limited, Auckland, New Zealand.
Sorkin
E M
EM
D000818:Animals; D002354:Carteolol / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D004304:Dosage Forms; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000188:drug therapy*
D004304:Dosage Forms; D002354:Carteolol